Rigosertib-Activated JNK1/2 Eliminate Tumor Cells through p66Shc Activation

Rigosertib-Activated JNK1/2 Eliminate Tumor Cells through p66Shc Activation

Rigosertib, via reactive oxygen species (ROS), stimulates cJun N-terminal kinases 1/2 (JNK1/2), which inactivate RAS/RAF signaling and thereby inhibit growth and survival of tumor cells. JNK1/2 are not only regulated by ROS—they in turn can also control ROS production. The prooxidant and cell death...

Full description

Bibliographic Details
Main Authors: Julia K. Günther, Aleksandar Nikolajevic, Susanne Ebner, Jakob Troppmair, Sana Khalid
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:Biology
Subjects:
p66Shc
Rigosertib
reactive oxygen species
cell death
Online Access:https://www.mdpi.com/2079-7737/9/5/99

Similar Items

Similar Items